{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:58Z","timestamp":1790821558614,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106750","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:34:13Z","timestamp":1757781253000},"page":"106750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis"],"prefix":"10.1016","volume":"104","author":[{"given":"Ning","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106750_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","article-title":"Revisiting the behavioral model and access to medical care: does it matter?","volume":"36","author":"Andersen","year":"1995","journal-title":"J. Health Soc. Behav."},{"key":"10.1016\/j.msard.2025.106750_bib0036","doi-asserted-by":"crossref","first-page":"449","DOI":"10.31083\/ph.2019.9515","article-title":"Comparison of Copaxone(R) and Synthon's therapeutically equivalent glatiramer acetate","volume":"74","author":"Arends","year":"2019","journal-title":"Pharmazie"},{"key":"10.1016\/j.msard.2025.106750_bib0029","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"key":"10.1016\/j.msard.2025.106750_bib0028","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1212\/WNL.0000000000012777","article-title":"Applying propensity score methods in clinical research in neurology","volume":"97","author":"Austin","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106750_bib0013","series-title":"Statpearls","article-title":"Glatiramer","author":"Babaesfahani","year":"2024"},{"key":"10.1016\/j.msard.2025.106750_bib0015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/0897190017725984","article-title":"Development of Glatopa(R) (Glatiramer Acetate): the first FDA-approved generic disease-modifying therapy for relapsing forms of multiple sclerosis","volume":"31","author":"Bell","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.msard.2025.106750_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","article-title":"Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database","volume":"6","author":"Boster","year":"2017","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106750_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.msard.2013.09.004","article-title":"Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates","volume":"3","author":"Campbell","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106750_bib0024","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2010.523670","article-title":"Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims","volume":"13","author":"Chastek","year":"2010","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2025.106750_bib0017","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamaneurol.2015.2154","article-title":"Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial","volume":"72","author":"Cohen","year":"2015","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106750_bib0007","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106750_bib0035","article-title":"Equivalent gene expression profiles between Glatopa and Copaxone(R)","volume":"10","author":"D'Alessandro","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2025.106750_bib0012","first-page":"741","article-title":"Marginal health care expenditure burden among U.S. Civilian noninstitutionalized individuals with Multiple sclerosis: 2010-2015","volume":"26","author":"Earla","year":"2020","journal-title":"J. Manage Care Spec. Pharm."},{"key":"10.1016\/j.msard.2025.106750_bib0037","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/phar.2517","article-title":"Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis","volume":"41","author":"Earla","year":"2021","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.msard.2025.106750_bib0032","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med. Care"},{"key":"10.1016\/j.msard.2025.106750_bib0006","first-page":"175","article-title":"Multiple sclerosis review","volume":"37","author":"Goldenberg","year":"2012","journal-title":"P. T."},{"key":"10.1016\/j.msard.2025.106750_bib0018","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/03007995.2020.1760808","article-title":"Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate","volume":"36","author":"Greenberg","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2025.106750_bib0001","first-page":"s141","article-title":"Overview and diagnosis of multiple sclerosis","volume":"22","author":"Hunter","year":"2016","journal-title":"Am. J. Manage Care"},{"key":"10.1016\/j.msard.2025.106750_bib0039","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14737175.2021.1886082","article-title":"Considering patient age when treating multiple sclerosis across the adult lifespan","volume":"21","author":"Jakimovski","year":"2021","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.msard.2025.106750_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-444-52001-2.00002-9","article-title":"Pathology of multiple sclerosis and related inflammatory demyelinating diseases","volume":"122","author":"Kutzelnigg","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.msard.2025.106750_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104019","article-title":"Health-related quality of life of patients with multiple sclerosis: analysis of ten years of national data","volume":"66","author":"Li","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106750_bib0041","article-title":"Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States","volume":"190","author":"Li","year":"2024","journal-title":"Prev. Med."},{"key":"10.1016\/j.msard.2025.106750_bib0042","article-title":"Infection risk associated with high-efficacy disease-modifying agents in multiple sclerosis: a retrospective cohort study","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.msard.2025.106750_bib0026","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106750_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106750_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMa"},{"key":"10.1016\/j.msard.2025.106750_bib0019","unstructured":"Merative. Merative MarketScan Research Databases. <https:\/\/www.merative.com\/content\/dam\/merative\/documents\/brief\/Marketscan_explainer_general.pdf> (2023). Accessed 10\/1 2023."},{"key":"10.1016\/j.msard.2025.106750_bib0020","unstructured":"Merative. MarketScan for life sciences researchers. https:\/\/www.merative.com\/content\/dam\/merative\/documents\/brief\/marketscan-research-databases-for-life-sciences-researchers.pdf Accessed 10\/1 2023."},{"key":"10.1016\/j.msard.2025.106750_bib0034","unstructured":"NICE. NICE Real-World Evidence Framework. www.nice.org.uk\/corporate\/ecd9\/chapter\/overview (2022). Accessed 8\/1\/2024."},{"key":"10.1016\/j.msard.2025.106750_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106750_bib0027","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.msard.2025.106750_bib0009","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1212\/WNL.0b013e31829a3388","article-title":"Mortality in patients with multiple sclerosis","volume":"81","author":"Scalfari","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106750_bib0038","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archinte.166.3.332","article-title":"The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions","volume":"166","author":"Shrank","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.msard.2025.106750_bib0016","unstructured":"Smith, S.G. Prescription trends in branded versus generic glatiramer acetate utilization among insurers for the treatment of multiple sclerosis in the United States. (2019)."},{"key":"10.1016\/j.msard.2025.106750_bib0021","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1212\/WNL.0b013e3182684707","article-title":"Recommendations for optimal ICD codes to study neurologic conditions: a systematic review","volume":"79","author":"St Germaine-Smith","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106750_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102741","article-title":"Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population","volume":"49","author":"Toliver","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106750_bib0022","unstructured":"Tomicki, S. & Pyenson, B.S. Multiple sclerosis: New perspectives on the patient journey: 2019 update. <https:\/\/us.milliman.com\/en\/insight\/multiple-sclerosis-new-perspectives-on-the-patient-journey-2019-update> (2019)."},{"key":"10.1016\/j.msard.2025.106750_bib0033","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2025.106750_bib0004","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106750_bib0014","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jns.2017.03.030","article-title":"Two decades of glatiramer acetate: from initial discovery to the current development of generics","volume":"376","author":"Weinstock-Guttman","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106750_bib0040","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106750_bib0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","article-title":"Infection risk in patients on multiple sclerosis therapeutics","volume":"29","author":"Williamson","year":"2015","journal-title":"CNS. Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:38:13Z","timestamp":1784345893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"alternative-id":["S2211034825004924"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106750","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106750"}}